DeNovX is ...
an innovative pharmaceutical company that provides platform products for pharmaceutical and medical nutrition uses. Our pharmaceutical products division is advancing the development of a treatment for ulcerative colitis. Our pharmaceutical technology division is focused on the commercialization of products to accelerate pharmaceutical development while creating new intellectual property (IP) for commercially relevant products.
Ulcerative colitis (UC) is a life-long disease with no known cure that affects approximately 1.3 million people in Canada, France, Germany, Great Britain, Italy, Japan, and the United States. Currently available therapies are not universally effective in the treatment of UC, and there exists a significant gap in the cost and effectiveness between the first-line therapy (5-aminosalicylate) and costly biologics. We believe that the drug we are developing, DNVX-078, is well situated to fill this gap and provide a new alternative to patients with mild to moderate ulcerative colitis.
Over 90% of active pharmaceutical ingredients (APIs) are crystalline solids, and our crystal development technologies reduce the risks associated with controlling the size, shape, and structure of these high value materials while creating new IP to enhance competitive advantage and to extend product life cycles.
Think Forward - to a new therapy alternative for ulcerative colitis, rational crystal screening and solid form controls.